PharmaNutra SpA (MIL:PHN) Interest Income: €0.6 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:PHN PharmaNutra SpA MIL:PHN
86 GF Score
Price €81.50
GF Value €73.29
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is PharmaNutra SpA Interest Income?

PharmaNutra SpA MIL:PHN -0.85% 86 Interest Income is €0.6 Mil as of Mar. 2026. GuruFocus rates MIL:PHN with a GF Score™ of 86/100 and a GF Value™ of €73.29 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. PharmaNutra SpA's interest income for the three months ended in Mar. 2026 was €0.2 Mil. Its interest income for the trailing twelve months (TTM) ended in Mar. 2026 was €0.6 Mil.

PharmaNutra SpA Interest Income Historical Data

* Premium members only.

The historical data trend for PharmaNutra SpA's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaNutra SpA Interest Income Chart

PharmaNutra SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.13 0.32 0.68 0.52

PharmaNutra SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.23 0.11 0.13 0.16
MIL:PHN
86GF Score
PharmaNutra SpA MIL:PHN
Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaNutra SpA Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Income →
What does a Interest Income of €0.6 Mil mean?
PharmaNutra SpA (MIL:PHN) has a Interest Income of €0.6 Mil as of Mar. 2026. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on PharmaNutra SpA and its competitors.
Is PharmaNutra SpA's Interest Income too high?
PharmaNutra SpA's current Interest Income is €0.6 Mil. Overall, PharmaNutra SpA has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmaNutra SpA's Interest Income compare to ZTS and UTHR?
PharmaNutra SpA's Interest Income of €0.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Income for a Drug Manufacturers company?
A good Interest Income depends on the Drug Manufacturers industry context. However, Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Income mean?
A high Interest Income can signal that a stock is expensive relative to its fundamentals. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on PharmaNutra SpA and its competitors. PharmaNutra SpA's current Interest Income is €0.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaNutra SpA stock overvalued right now?
Based on GuruFocus' analysis, PharmaNutra SpA (MIL:PHN) is currently considered Modestly Overvalued. The stock's GF Value™ is €73.29, compared to a current price of €81.50 — trading 11.2% above its estimated fair value. The current Interest Income is €0.6 Mil. PharmaNutra SpA's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Income calculated?
Interest Income is calculated from a company's financial statements. For PharmaNutra SpA (MIL:PHN), the current Interest Income is €0.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmaNutra SpA (MIL:PHN) Overvalued in 2026?

Based on GuruFocus' analysis, PharmaNutra SpA stock appears to be overvalued. The current stock price of €81.50 is trading 11.2% above its estimated GF Value™ of €73.29. GuruFocus considers PharmaNutra SpA to be Modestly Overvalued.

Key valuation signals for MIL:PHN:

  • Interest Income: €0.6 Mil
  • GF Value™: €73.29 vs. price of €81.50 (11.2% above fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the MIL:PHN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmaNutra SpA Business Description

Other Exchanges PHNm:UK761:Germany
Address Via Campodavela 1, Pisa, ITA, 56122
PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, and other regions.
86GF Score

Get the complete analysis for MIL:PHN

Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€81.50
Price
€73.29
GF Value